Presentations & Publications

We are proud of our scientific progress, much of which has been documented via various presentations and publications.

Since 2011, our proprietary platform has enabled the design of three new clinical drug candidates, resulting in four clinical programs. Our scientific progress has been documented in various national and international presentations and publications.

October 2018

Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity

February 2018

PRN473, an inhibitor of Bruton’s tyrosine kinase, inhibits neutrophil recruitment via inhibition of macrophage antigen-1 signalling

February 2018

Clinical endpoint analysis of the Believe-PV phase 2 study of PRN1008 in pemphigus

December 2017

PRN1008, A Reversible Covalent BTK Inhibitor in Clinical Development for Immune Thrombocytopenic Purpura

November 2017

ITK and RLK Inhibitor PRN694 Improves Skin Disease in Two Mouse Models of Psoriasis

November 2017

A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton’s tyrosine kinase, in healthy volunteers

October 2017

The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance

October 2017

PRN2246, a potent and selective blood brain barrier penetrating BTK inhibitor, exhibits efficacy in central nervous system immune models

Advancing Promising Therapies

Principia is now a Sanofi company.

As of September 28, 2020, Sanofi and Principia have joined forces to expand and accelerate the potential benefits of therapies for patients with immune-mediated diseases. We will work together to bring these novel therapies to patients faster. Read press release.

Enter Website